Oral exemestane 25 mg/day for 2–3 years of adjuvant therapy was generally more effective than 5 years of continuous adjuvant tamoxifen in the treatment of postmenopausal women with early-stage estrogen receptor-positive/unknown receptor status breast in a large well-designed [ citation needed ] trial. Preliminary data from the open-label TEAM trial comparing exemestane with tamoxifen indicated in 2009 that exemestane 25 mg/day is also effective in the primary adjuvant treatment of early-stage breast cancer in postmenopausal women. 
Dutasteride was patented in 1996  and was first described in the scientific literature in 1997.  It was approved by the FDA for the treatment of BPH in November 2001 and was introduced into the . market the following year under the brand name Avodart.  Dutasteride has subsequently been introduced in many other countries as well, including throughout Europe and South America .  The patent protection of dutasteride expired in November 2015 and the drug has since become available in the . in a variety of low-cost generic formulations .